Metabolic disease: Receptor antibodies as novel therapeutics for diabetes

Science Translational Medicine

Volumn 3, Issue 113, 2011, Pages

  Ussar, Siegfried ^a   Vienberg, Sara G ^a   Kahn, C Ronald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INSULIN RECEPTOR; OSTEOGENIC PROTEIN 1; RECEPTOR ANTIBODY;

ALTERNATIVE RNA SPLICING; BROWN ADIPOSE TISSUE; DIABETES MELLITUS; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; LIGAND BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

EID: 83655165302     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003447     Document Type: Review

References (18)

1. A.-L. Wu, G. Kolumam, S. Stawicki, Y. Chen, J. Li, J. Zavala- Solorio, K. Phamluong, B. Feng, L. Li, S. Marsters, L. Kates, N. van Bruggen, M. Leabman, A. Wong, D. West, H. Stern, E. Luis, H. Seon Kim, D. Yansura, A. S. Peterson, E. Filvaroff, Y. Wu, J. Sonoda, Amelioration of type 2 diabetes by antibody-mediated activation of fi broblast growth factor receptor 1. Sci. Transl. Med. 3, 113ra126 (2011).
2. K. Michalek, S. A. Morshed, R. Latif, T. F. Davies, TSH receptor autoantibodies. Autoimmun. Rev. 9, 113-116 (2009).
3. J. S. Flier, C. R. Kahn, J. Roth, Receptors, antireceptor antibodies and mechanisms of insulin resistance. N. Engl. J. Med. 300, 413-419 (1979).
4. B. Lang, A. Vincent, Autoimmune disorders of the neuromuscular junction. Curr. Opin. Pharmacol. 9, 336-340 (2009).
5. S. A. Kliewer, D. J. Mangelsdorf, Fibroblast growth factor 21: From pharmacology to physiology. Am. J. Clin. Nutr. 91, 254S-257S (2010).
6. A. Kharitonenkov, T. L. Shiyanova, A. Koester, A. M. Ford, R. Micanovic, E. J. Galbreath, G. E. Sandusky, L. J. Hammond, J. S. Moyers, R. A. Owens, J. Gromada, J. T. Brozinick, E. D. Hawkins, V. J. Wroblewski, D. S. Li, F. Mehrbod, S. R. Jaskunas, A. B. Shanafelt, FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635 (2005).
7. H. Kurosu, M. Choi, Y. Ogawa, A. S. Dickson, R. Goetz, A. V. Eliseenkova, M. Mohammadi, K. P. Rosenblatt, S. A. Kliewer, M. Kuro-o, Tissue-specifi c expression of betaKlotho and fi broblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695 (2007).
8. A. Bendele, J. Seely, C. Richey, G. Sennello, G. Shopp, Short communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42, 152-157 (1998).
9. F. M. Fisher, P. C. Chui, P. J. Antonellis, H. A. Bina, A. Kharitonenkov, J. S. Flier, E. Maratos-Flier, Obesity is a fi broblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781-2789 (2010).
10. J. Wesche, K. Haglund, E. M. Haugsten, Fibroblast growth factors and their receptors in cancer. Biochem. J. 437, 199-213 (2011).
11. D. A. Sarruf, J. P. Thaler, G. J. Morton, J. German, J. D. Fischer, K. Ogimoto, M. W. Schwartz, Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59, 1817-1824 (2010).
12. Y. H. Tseng, E. Kokkotou, T. J. Schulz, T. L. Huang, J. N. Winnay, C. M. Taniguchi, T. T. Tran, R. Suzuki, D. O. Espinoza, Y. Yamamoto, M. J. Ahrens, A. T. Dudley, A. W. Norris, R. N. Kulkarni, C. R. Kahn, New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 454, 1000-1004 (2008).
13. P. R. Srinivas, A. S. Wagner, L. V. Reddy, D. D. Deutsch, M. A. Leon, A. S. Goustin, G. Grunberger, Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol. Endocrinol. 7, 1445-1455 (1993).
14. B. A. Maddux, Y. N. Chang, D. Accili, O. P. McGuinness, J. F. Youngren, I. D. Goldfi ne, Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am. J. Physiol. Endocrinol. Metab. 290, E746-E749 (2006).
15. A. Filipovich, I. Gehrke, S. J. Poll-Wolbeck, K. A. Kreuzer, Physiological inhibitors of Wnt signaling. Eur. J. Haematol. 86, 453-465 (2011).
16. E. A. Partridge, C. Le Roy, G. M. Di Guglielmo, J. Pawling, P. Cheung, M. Granovsky, I. R. Nabi, J. L. Wrana, J. W. Dennis, Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306, 120-124 (2004).
17. J. A. Corbin, V. Bhaskar, I. D. Goldfi ne, D. H. Bedinger, H. F. Kuan, L. Gross, A. Lau, M. Handa, S. R. Watson, L. Webster, R. Levy, B. A. Maddux, S. Wijesuriya, N. Liu, X. Wu, D. Chemla-Vogel, A. J. Narasimha, S. R. Lee, C. Tran, M. L. White, High affi nity insulin receptor antibodies sensitize the insulin receptor to insulin and restore glycemic control in murine models of diabetes. Diabetes 60, A276 (2011).
18. W. Gu, H. Yan, K. A. Winters, R. Komorowski, S. Vonderfecht, L. Atangan, G. Sivits, D. Hill, J. Yang, V. Bi, Y. Shen, S. Hu, T. Boone, R. A. Lindberg, M. M. Véniant, Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J. Pharmacol. Exp. Ther. 331, 871-881 (2009).